Publications
Editorials 2006, 2001
Reviews 2006, 2002, 2001, 2000
Primary Literature 2006, 2005, 2004, 2003, 2002, 2001, 2000, 1999, 1998, 1996, 1994
Editorials
2006
| Marsh S, McLeod HL. | |
| Pharmacogenomics: from bedside to clinical practice. | |
| Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R89-93. | |
| Grice GR, Seaton TL, Woodland AM, McLeod HL. | |
| Defining the opportunity for pharmacogenetic intervention in primary care. | |
| Pharmacogenomics. 2006 Jan;7(1):61-5. | |
2001
| McLeod HL. | |
| Pharmacogenetics: more than skin deep. | |
| Nat Genet. 2001 Nov;29(3):247-8. | |
Reviews
2006
| Marsh S, Van Booven DJ, McLeod HL. | |
| Global pharmacogenetics: giving the genome to the masses | |
| Pharmacogenomics. 2006 Jun;7(4):625-631. | |
2002
| Ma MK, Woo MH, McLeod HL. | |
| Genetic basis of drug metabolism. | |
| Am J Health Syst Pharm. 2002 Nov 1;59(21):2061-9. | |
| McLeod HL, Siva C. | |
| The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. | |
| Pharmacogenomics. 2002 Jan;3(1):89-98. | |
2001
| Marsh S, McLeod HL. | |
| Thymidylate synthase pharmacogenetics in colorectal cancer. | |
| Clin Colorectal Cancer. 2001 Nov;1(3):175-8; discussion 179-81. | |
| McLeod HL. | |
| Race and responsiveness to drugs for heart failure. | |
| N Engl J Med. 2001 Sep 6;345(10):766-7; author reply 767-8. | |
2000
| McLeod HL, Krynetski EY, Relling MV, Evans WE. | |
| Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. | |
| Leukemia. 2000 Apr;14(4):567-72. | |
Primary Literature
2006
| Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS. | |
| Population variation in VKORC1 haplotype structure. | |
| J Thromb Haemost. 2006 Feb;4(2):473-4. | |
2005
| King CR, Yu J, Freimuth RR, McLeod HL, Marsh S. | |
| Interethnic variability of ERCC2 polymorphisms. | |
| Pharmacogenomics J. 2005;5(1):54-9. | |
| Maxwell TJ, Ameyaw MM, Pritchard S, Thornton N, Folayan G, Githang'a J, Indalo A, Tariq M, Mobarek A, Evans DA, Ofori-Adjei D, Templeton AR, McLeod HL. | |
| Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. | |
| Int J Mol Med. 2005 Oct;16(4):573-80. | |
| Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T. | |
| A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. | |
| Biochem Pharmacol. 2005 Sep 1;70(5):801-8. | |
2004
| de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL. | |
| ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. | |
| Clin Cancer Res. 2004 Sep 1;10(17):5889-94. | |
| Lanfear DE, Marsh S, Cresci S, Shannon WD, Spertus JA, McLeod HL. | |
| Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. | |
| J Am Coll Cardiol. 2004 Jul 7;44(1):165-7. | |
| Ranganathan P, Culverhouse R, Marsh S, Ahluwalia R, Shannon WD, Eisen S, McLeod HL. | |
| Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. | |
| Pharmacogenomics. 2004 Jul;5(5):559-69. | |
| Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T. | |
| A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. | |
| Clin Pharmacol Ther. 2004 Dec;76(6):519-27. | |
| Lanfear DE, Marsh S, Cresci S, Spertus JA, McLeod HL. | |
| Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure. | |
| Pharmacogenomics. 2004 Jul;5(5):553-8. | |
| Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL. | |
| Pharmacogenomic assessment of carboxylesterases 1 and 2. | |
| Genomics. 2004 Oct;84(4):661-8. | |
| Marsh S, King CR, Ahluwalia R, McLeod HL. | |
| Distribution of ITPA P32T alleles in multiple world populations. | |
| J Hum Genet. 2004;49(10):579-81. | |
| Nakajima M, Yoshida R, Fukami T, McLeod HL, Yokoi T. | |
| Novel human CYP2A6 alleles confound gene deletion analysis. | |
| FEBS Lett. 2004 Jul 2;569(1-3):75-81. | |
| Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL. | |
| Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. | |
| Pharmacogenomics J. 2004;4(5):307-14. | |
| Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T. | |
| A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. | |
| Pharmacogenetics. 2004 May;14(5):329-32. | |
| Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. | |
| Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. | |
| Thromb Haemost. 2004 Jan;91(1):87-94. | |
2003
| Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. | |
| Irinotecan pathway genotype analysis to predict pharmacokinetics. | |
| Clin Cancer Res. 2003 Aug 15;9(9):3246-53. | |
| Marsh S, McLeod HL. | |
| Crohn's disease: ethnic variation in CARD15 genotypes. | |
| Gut. 2003 May;52(5):770. | |
| Ahluwalia R, Freimuth R, McLeod HL, Marsh S. | |
| Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. | |
| Clin Chem. 2003 Oct;49(10):1661-4. | |
2002
| McLeod HL. | |
| Pharmacokinetic differences between ethnic groups. | |
| Lancet. 2002 Jan 5;359(9300):78. | |
2001
| Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, McLeod HL, Konishi F, Maeda H, Yamakido M. | |
| Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. | |
| Pharmacogenetics. 2001 Apr;11(3):275-8. | |
| Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. | |
| MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. | |
| Pharmacogenetics. 2001 Apr;11(3):217-21. | |
| Evans DA, McLeod HL, Pritchard S, Tariq M, Mobarek A. | |
| Interethnic variability in human drug responses. | |
| Drug Metab Dispos. 2001 Apr;29(4 Pt 2):606-10. | |
2000
| Ameyaw MM, Syvanen AC, Ulmanen I, Ofori-Adjei D, McLeod HL. | |
| Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population. | |
| Hum Mutat. 2000 Nov;16(5):445-6. | |
| Marsh S, Ameyaw MM, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL. | |
| Novel thymidylate synthase enhancer region alleles in African populations. | |
| Hum Mutat. 2000 Dec;16(6):528. | |
| Ameyaw MM, Thornton N, McLeod HL. | |
| Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. | |
| J Natl Cancer Inst. 2000 Dec 6;92(23):1947. | |
| Morsman JM, Sludden J, Ameyaw MM, Githang'A J, Indalo A, Ofori-Adjei D, McLeod HL. | |
| Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. | |
| Br J Clin Pharmacol. 2000 Sep;50(3):269-72. | |
| Tayeb MT, Clark C, Ameyaw MM, Haites NE, Evans DA, Tariq M, Mobarek A, Ofori-Adjei D, McLeod HL. | |
| CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. | |
| Pharmacogenetics. 2000 Nov;10(8):753-6. | |
1999
| McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw MM, Powrie RH, Booth L, Collie-Duguid ES. | |
| Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. | |
| Pharmacogenetics. 1999 Dec;9(6):773-6. | |
| Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. | |
| Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. | |
| Genomics. 1999 Jun 15;58(3):310-2. | |
| Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod HL. | |
| The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. | |
| Pharmacogenetics. 1999 Feb;9(1):37-42. | |
| Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. | |
| Thiopurine methyltransferase alleles in British and Ghanaian populations. | |
| Hum Mol Genet. 1999 Feb;8(2):367-70. | |
1998
| McLeod HL, Syvanen AC, Githang'a J, Indalo A, Ismail D, Dewar K, Ulmanen I, Sludden J. | |
| Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. | |
| Pharmacogenetics. 1998 Jun;8(3):195-9. | |
1996
| McMurrough J, McLeod HL. | |
| Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. | |
| Br J Clin Pharmacol. 1996 May;41(5):425-7. | |
1994
| McLeod HL, Fang L, Luo X, Scott EP, Evans WE. | |
| Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. | |
| J Pharmacol Exp Ther. 1994 Jul;270(1):26-9. | |
| McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. | |
| Thiopurine methyltransferase activity in American white subjects and black subjects. | |
| Clin Pharmacol Ther. 1994 Jan;55(1):15-20. | |